Clinical trials
Gliosarcoma clinical trials
Below are recruiting gliosarcoma clinical trials, each written for real people, not researchers. We’re tracking 16 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07089641RecruitingPhase 1
Testing a new pill for EGFR-mutated glioblastoma
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
Los Angeles, CaliforniaAges 18 years+ - NCT04991870RecruitingPhase 1
Early-stage immune cell therapy for recurrent grade 4 brain tumors
This Phase 1 trial tests a gene-edited immune cell treatment given into the brain to treat recurrent (returning) grade 4 glioblastoma or related tumors. It aims to find a safe dose and see whether the treatment can slow tumor growth.
Houston, TexasAges 12 years+ - NCT07301268RecruitingPhase 2
GI-102 with or without pembrolizumab before brain surgery
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
Rochester, MinnesotaAges 18 years+ - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT03896568RecruitingPhase 1
Trial of stem cell therapy for recurrent high-grade brain tumors
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
Houston, TexasAges 18 years+ - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT05052957RecruitingPhase 2
Autologous stem cell rescue for newly diagnosed brain tumor
This trial tests giving a patient’s own stem cells back to help the bone marrow recover after treatment for newly diagnosed glioblastoma or gliosarcoma. It may help reduce blood-count problems so treatment can be given more safely.
Cleveland, OhioAges 18–75 - NCT05084430RecruitingPhase 1/Phase 2
Pembrolizumab plus M032 for recurrent brain tumors
This early-phase study tests the safety and early signs of benefit of combining pembrolizumab with M032 in people with certain aggressive brain tumors. You may be considered if you have a glioma tumor that can potentially be removed by surgery.
Birmingham, AlabamaAges 18 years+ - NCT05465954RecruitingPhase 2
Testing efinetakin and pembrolizumab for recurrent glioblastoma
This Phase 2 trial studies efinetakin alfa plus pembrolizumab for adults with recurrent glioblastoma (a fast-growing brain tumor). It aims to shrink or control the tumor and help patients live longer and better after standard treatments like surgery, radiation, and temozolomide.
Rochester, MinnesotaAges 18 years+ - NCT05698524RecruitingPhase 1
Temodar plus an investigational pill for recurrent brain cancer
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
Omaha, NebraskaAges 19 years+ - NCT05756985Recruiting
Providing fresh brain tissue to better understand glioblastoma
This study aims to improve understanding of glioblastoma (and gliosarcoma) by preserving live, usable brain-tissue samples during brain surgery. If you’re having repeat tumor surgery or your scans suggest these cancers, the study may ask to collect tissue for research.
Miami, FloridaAges 18 years+ - NCT05864534RecruitingPhase 2
Ultrasound plus immune treatment after new glioblastoma diagnosis
This trial tests whether using focused ultrasound to help adjust the immune system can improve outcomes for people with newly diagnosed glioblastoma. You’d already complete standard brain radiation (with or without temozolomide), then undergo an ultrasound-based immune modulation approach.
Chicago, IllinoisAges 18 years+ - NCT06934889RecruitingPhase 1
Study of ABBV-637 or ABBV-155 with ERAS-801 for recurrent glioblastoma
This trial tests two new drugs (ABBV-637 or ABBV-155) combined with ERAS-801 for people with recurrent glioblastoma (a type of brain cancer). It may help if your tumor has a specific genetic change (EGFR amplification) and you are having surgery to remove part of the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06954636Recruiting
Smell test to predict glioblastoma outcomes (newly diagnosed)
This study looks at whether a simple smell test can help predict how glioblastoma will progress. It is for people who are newly diagnosed and have not started treatment yet.
EssenAges 18 years+ - NCT07134842RecruitingPhase 1
Immunotherapy before standard brain cancer treatment
This trial tests giving the immunotherapy drug ipilimumab before the usual treatment for newly diagnosed glioblastoma (a type of brain cancer). The goal is to see if this approach is safe and possible, and whether it might help the immune system fight the tumor better.
London, Greater LondonAges 18 years+ - NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+
Hear when a new Gliosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gliosarcoma?
- Yes. Clin2 currently lists 16 recruiting gliosarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gliosarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gliosarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.